Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Need to clarify & very clear

<< Previous

Bullboard Posts

Next >>

Comment by CMHarring218431on Mar 06, 2024 3:45pm

110 Views

Post# 35918889

RE:RE:RE:RE:Need to clarify & very clear

Hey Buck
I found the last few, especially the highlighted comments, to be very on target, noteable and reaffirming. How do you not see the relevance of so many trends which are focusing on what Pela offers? I know.... you do realize but just keep focusing on the negative. It apparently suits you!

<< Previous

Bullboard Posts

Next >>

B2Gold stock buckles under news of labour strike in Mali